505 related articles for article (PubMed ID: 34487060)
41. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
Christie A; Brooks JT; Hicks LA; Sauber-Schatz EK; Yoder JS; Honein MA;
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(30):1044-1047. PubMed ID: 34324480
[TBL] [Abstract][Full Text] [Related]
42. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
43. Cancer patients and internal medicine patients attitude towards COVID-19 vaccination in Poland.
Kufel-Grabowska J; Bartoszkiewicz M; Ramlau R; Litwiniuk M
Adv Clin Exp Med; 2021 Aug; 30(8):805-811. PubMed ID: 34286517
[TBL] [Abstract][Full Text] [Related]
44. Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain.
Lechosa-Muñiz C; Paz-Zulueta M; Mendez-Legaza JM; Irure-Ventura J; Cuesta González R; Calvo Montes J; López-Hoyos M; Llorca J; Cabero-Pérez MJ
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444579
[TBL] [Abstract][Full Text] [Related]
45. The impact of COVID-19 vaccines on the Case Fatality Rate: The importance of monitoring breakthrough infections.
di Lego V; Sánchez-Romero M; Prskawetz A
Int J Infect Dis; 2022 Jun; 119():178-183. PubMed ID: 35398301
[TBL] [Abstract][Full Text] [Related]
46. Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement.
Grau S; Ferrández O; Martín-García E; Maldonado R
Clin Microbiol Infect; 2021 Nov; 27(11):1698.e1-1698.e4. PubMed ID: 34129908
[TBL] [Abstract][Full Text] [Related]
47. The Effectiveness of a Diverse COVID-19 Vaccine Portfolio and Its Impact on the Persistence of Positivity and Length of Hospital Stays: The Veneto Region's Experience.
Cocchio S; Zabeo F; Facchin G; Piva N; Furlan P; Nicoletti M; Saia M; Tonon M; Mongillo M; Russo F; Baldo V
Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062767
[TBL] [Abstract][Full Text] [Related]
48. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Guevara M; Fernández-Huerta M; Burgui C; Casado I; Portillo ME; Navascués A; Ezpeleta C; Castilla J; ;
Euro Surveill; 2021 Sep; 26(39):. PubMed ID: 34596016
[TBL] [Abstract][Full Text] [Related]
49. The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis.
Marra AR; Kobayashi T; Suzuki H; Alsuhaibani M; Schweizer ML; Diekema DJ; Tofaneto BM; Bariani LM; Auler MA; Salinas JL; Edmond MB; Pinho JRR; Rizzo LV
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e22. PubMed ID: 36310810
[TBL] [Abstract][Full Text] [Related]
50. 'COVID arm' - histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine.
Kempf W; Kettelhack N; Kind F; Courvoisier S; Galambos J; Pfaltz K
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e730-e732. PubMed ID: 34242422
[No Abstract] [Full Text] [Related]
51. PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio.
Suah JL; Tok PSK; Ong SM; Husin M; Tng BH; Sivasampu S; Thevananthan T; Appannan MR; Muhamad Zin F; Mohd Zin S; Yahaya H; Rusli N; Ujang MF; Mohd Ibrahim H; Abdullah NH; Peariasamy KM
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960126
[TBL] [Abstract][Full Text] [Related]
52. SARS-CoV2 vaccine boosters for India.
Kang G
Indian J Med Microbiol; 2022; 40(1):1-2. PubMed ID: 34991914
[No Abstract] [Full Text] [Related]
53. Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines.
Lapi F; Domnich A; Marconi E; Rossi A; Grattagliano I; Lagolio E; Medea G; Sessa A; Cricelli I; Icardi G; Cricelli C
Expert Rev Vaccines; 2022 Mar; 21(3):377-384. PubMed ID: 34913796
[TBL] [Abstract][Full Text] [Related]
54. Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy.
Colaneri M; Pieri TC; Roda S; Ricciardi A; Gotti M; Ferrari J; Arcaini L; Rattotti S; Piralla A; Giardina F; Ferrari G; Sacchi P; Zuccaro V; Baldanti F; Bruno R
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556068
[TBL] [Abstract][Full Text] [Related]
55. Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
Levin Y; Balakirski NM; Caraco Y; Ben-Ami E; Atsmon J; Marcus H
Vaccine; 2021 May; 39(21):2821-2823. PubMed ID: 33896663
[No Abstract] [Full Text] [Related]
56. Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study.
Pálinkás A; Sándor J
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891173
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of COVID-19 vaccines: findings from real-world studies.
Henry DA; Jones MA; Stehlik P; Glasziou PP
Med J Aust; 2022 May; 216(8):431. PubMed ID: 35352352
[No Abstract] [Full Text] [Related]
58. Can natural immunity partially replace vaccine against SARS-COV2 infection? A small single center study.
Bonetti G; Chitoni G; Bettinardi A; Borrelli G; Fiordalisi G; Marino A; Menolfi A; Volpi R; Manelli F; Cotelli MS
Minerva Med; 2023 Oct; 114(5):739-742. PubMed ID: 33709674
[No Abstract] [Full Text] [Related]
59. Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study.
Coppola C; Masarone M; Bartoli M; Staiano L; Coppola R; Torre P; Conforti M; Amoruso D; Gardini I; Persico M
J Viral Hepat; 2022 Feb; 29(2):171-173. PubMed ID: 34585821
[No Abstract] [Full Text] [Related]
60. COVID-19 vaccine effectiveness in preventing deaths among high-risk sgroups in Tamil Nadu, India.
Jaiswal A; Subbaraj V; Vivian Thangaraj JW; Murhekar MV; Muliyil J
Indian J Med Res; 2021 May; 153(5&6):689-691. PubMed ID: 34213434
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
